A survey conducted by the National Comprehensive Cancer Network found that 93% of its 27 member institutions are experiencing shortages of carboplatin, and 70% lack cisplatin.
Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.
